Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price

Perspective Therapeutics (NYSE:CATX - Get Free Report) had its target price dropped by analysts at Truist Financial from $21.00 to $10.00 in a report released on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Truist Financial's price objective points to a potential upside of 412.82% from the stock's previous close.

CATX has been the topic of several other reports. Wedbush reissued an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research report on Monday, March 31st. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Monday, March 10th. Scotiabank started coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $15.00 price target for the company. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Perspective Therapeutics has a consensus rating of "Buy" and a consensus target price of $12.75.

Perspective Therapeutics Price Performance

Shares of NYSE CATX traded up $0.09 during midday trading on Monday, reaching $1.95. 1,020,989 shares of the stock were exchanged, compared to its average volume of 1,016,536. The firm has a 50-day simple moving average of $2.53 and a two-hundred day simple moving average of $5.43. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $19.05.

Insider Transactions at Perspective Therapeutics

In other news, Director Robert F. Williamson III bought 38,145 shares of the business's stock in a transaction that occurred on Monday, March 31st. The shares were purchased at an average cost of $2.14 per share, for a total transaction of $81,630.30. Following the completion of the purchase, the director now owns 108,982 shares of the company's stock, valued at approximately $233,221.48. This represents a 53.85 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor acquired 22,026 shares of the company's stock in a transaction on Friday, March 28th. The stock was purchased at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the transaction, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. The trade was a 58.96 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 115,696 shares of company stock worth $256,344 in the last 90 days. Insiders own 3.52% of the company's stock.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. grew its position in Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company's stock worth $5,788,000 after purchasing an additional 298,778 shares during the last quarter. State Street Corp grew its stake in shares of Perspective Therapeutics by 119.6% in the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company's stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Perspective Therapeutics by 1,302.7% in the third quarter. BNP Paribas Financial Markets now owns 47,565 shares of the company's stock valued at $635,000 after purchasing an additional 44,174 shares during the period. Vontobel Holding Ltd. purchased a new stake in shares of Perspective Therapeutics during the fourth quarter worth approximately $51,000. Finally, Barclays PLC lifted its holdings in shares of Perspective Therapeutics by 587.9% during the third quarter. Barclays PLC now owns 114,075 shares of the company's stock worth $1,523,000 after purchasing an additional 97,493 shares during the period. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.